Publications by authors named "Deborah Hankey"

Claim this Profile
L
Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.
Sarah Al-Izki, Gareth Pryce, Deborah J R Hankey, Katie Lidster, Stephanie M von Kutzleben

Brain· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation of pre-confluent retinal cells increases graft viability in vitro and in vivo: a mouse model.
Kevin P Kennelly, Deborah M Wallace, Toby M Holmes, Deborah J Hankey, Timothy S Grant

PLoS One· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.
Gareth Pryce, Janet K O'Neill, J Ludovic Croxford, Sandra Amor, Deborah J Hankey

J Neuroimmunol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction.
Rachel Harry, Matthew Gegg, Deborah Hankey, Hadi Zambarakji, Gareth Pryce

J Immunol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.
Gareth Pryce, Zubair Ahmed, Deborah J R Hankey, Samuel J Jackson, J Ludovic Croxford

Brain· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis.
Claire E Walters, Gareth Pryce, Deborah J R Hankey, Said M Sebti, Andrew D Hamilton

J Immunol· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors.
Jason W Brooks, Gareth Pryce, Tiziana Bisogno, Siân I Jaggar, Deborah J R Hankey

Eur J Pharmacol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis